



Nova Leap Health Corp.

**Condensed Interim Consolidated Financial Statements
For the three and nine months ended September 30, 2018 and 2017**

**(Unaudited)
(United States dollars)**

Nova Leap Health Corp.

Condensed Consolidated Statement of Financial Position (Unaudited - United States dollars)

	September 30, 2018	December 31, 2017
	\$	\$
ASSETS		
Current assets		
Cash and cash equivalents	1,820,640	136,820
Accounts receivable	1,207,762	269,947
Prepaid expenses	145,056	59,153
Total current assets	3,173,458	465,920
Non-current assets		
Property, plant and equipment (note 4)	32,763	3,225
Intangible assets (note 5)	1,403,061	226,493
Goodwill (note 6)	7,559,262	2,116,500
Deferred income tax asset	161,389	102,308
Total non-current assets	9,156,475	2,448,526
TOTAL ASSETS	12,329,933	2,914,446
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities (note 7)	726,885	452,890
Client deposits payable	64,776	99,463
Promissory note (note 8)	455,553	-
Demand loans (note 9)	3,789,537	540,545
Total current liabilities	5,036,751	1,092,898
Non-current liabilities		
Promissory note (note 8)	496,077	-
Deferred tax liability	97,958	-
Total non-current liabilities	594,035	-
TOTAL LIABILITIES	5,630,786	1,092,898
SHAREHOLDERS' EQUITY		
Common shares (note 10)	7,929,116	2,596,157
Warrants (note 11)	921,726	399,980
Contributed surplus (note 13)	228,709	107,975
Accumulated other comprehensive (loss) income	(50,689)	58,564
Deficit	(2,329,715)	(1,341,128)
TOTAL SHAREHOLDERS' EQUITY	6,699,147	1,821,548
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	12,329,933	2,914,446

Going concern (note 1)

Subsequent events (note 17)

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.

Approved on behalf of the Board of Directors

“Michael O’Keefe”

(signed)

Director

“Christopher Dobbin”

(signed)

Director

Nova Leap Health Corp.

Condensed Consolidated Statement of Loss and Comprehensive Loss (Unaudited - United States dollars)

	For the three months ended		For the nine months ended	
	September 30, 2018	September 30, 2017	September 30, 2018	September 30, 2017
	\$	\$	\$	\$
Revenues				
Net service revenue	2,871,010	88,682	6,561,097	168,649
Operating expenses				
Cost of Service	1,991,835	54,653	4,451,057	107,880
	879,175	34,029	2,110,040	60,769
Corporate and administrative expenses				
Head office and operations management	585,379	90,420	1,536,577	244,448
Corporate & administrative - other	252,439	115,171	653,165	299,427
Amortization (notes 4 and 5)	177,472	795	392,602	1,809
Stock based compensation	26,248	-	134,395	-
Impairment loss (note 5)	-	2,505	-	3,891
	1,041,538	208,891	2,716,739	549,575
Loss from operating activities	162,363	174,862	606,699	488,806
Net finance, acquisition related expenses and foreign exchange				
Finance income	-	412	-	873
Finance expense	(91,813)	-	(200,973)	(4,421)
Foreign exchange gain (loss)	(69,608)	(30,526)	75,104	(32,242)
Acquisition related expenses	(83,673)	(63,028)	(307,075)	(82,881)
	(245,094)	(93,142)	(432,944)	(118,671)
Deferred income tax recovery	29,075	-	51,056	16,592
Net loss	378,382	268,004	988,587	590,885
Items that will be reclassified subsequently to profit or loss				
Exchange loss (gain) on translation to presentation currency	(96,429)	(63,480)	109,253	(57,328)
Total comprehensive loss	281,953	204,524	1,097,840	533,557
Weighted average number of shares outstanding during the period (note 14)	53,679,899	21,919,293	44,819,522	17,773,169
Basic and diluted loss per share	\$ (0.01)	\$ (0.01)	\$ (0.02)	\$ (0.03)

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.

Nova Leap Health Corp.

Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited - United States dollars)

	Common shares	Share capital \$	Warrants \$	Contributed surplus \$	Accumulated other comprehensive income \$	Deficit \$	Total equity \$
Balance – January 1, 2018	29,722,100	2,596,157	399,980	107,975	58,564	(1,341,128)	1,821,548
Units issued for cash, net of issuance costs (note 10)	27,964,611	5,275,669	345,579	-	-	-	5,621,248
Broker shares issued (note 10)	80,000	15,787	-	-	-	-	15,787
Broker warrants issued (note 11)	-	-	176,477	-	-	-	176,477
Agent options exercised (notes 12 & 13)	350,000	40,736	-	(13,661)	-	-	27,075
Broker warrants exercised (notes 10 & 11)	2,400	767	(310)	-	-	-	457
Stock based compensation (notes 12 & 13)	-	-	-	134,395	-	-	134,395
Net loss for the period	-	-	-	-	-	(988,587)	(988,587)
Other comprehensive loss for the period	-	-	-	-	(109,253)	-	(109,253)
Balance – September 30, 2018	58,119,111	7,929,116	921,726	228,709	(50,689)	(2,329,715)	6,699,147
Balance – January 1, 2017	13,500,000	510,801	-	116,109	7,991	(489,519)	145,382
Units issued for cash, net of issuance costs	8,762,500	1,082,985	225,935	-	-	-	1,308,920
Redemption of convertible debt	-	-	-	(8,134)	-	-	(8,134)
Net loss for the period	-	-	-	-	-	(590,885)	(590,885)
Other comprehensive income for the period	-	-	-	-	57,328	-	57,328
Balance – September 30, 2017	22,262,500	1,593,786	225,935	107,975	65,319	(1,080,404)	912,611

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.

Nova Leap Health Corp.

Consolidated Statement of Cash Flows (Unaudited - United States dollars)

	For the three months ended		For the nine months ended	
	September 30, 2018	September 30, 2017	September 30, 2018	September 30, 2017
	\$	\$	\$	\$
Cash provided by (used in)				
Operating activities				
Net loss for the period	(378,382)	(268,039)	(988,587)	(590,885)
Amortization (notes 4 and 5)	177,472	795	392,602	1,809
Deferred income tax recovery	(29,075)	-	(51,056)	(16,592)
Impairment loss (note 5)	-	2,505	-	3,891
Loss on disposal of property, plant and equipment	-	-	1,325	-
Stock based compensation (note 12)	26,248	-	134,395	-
Finance expense	91,813	-	200,973	(2,136)
Unrealized foreign exchange (gain) loss	78,397	50,816	(99,297)	58,806
Net changes in non-cash working capital balances related to				
Change in accounts receivable	45,522	(42,162)	(937,815)	(36,610)
Change in prepaid expense	23,784	(18,809)	(85,903)	(11,504)
Change in accounts payable and accrued liabilities	(81,938)	134,747	273,995	139,531
Change in client deposits payable	(10,796)	54,000	(34,687)	54,000
	(56,955)	(86,147)	(1,194,055)	(399,690)
Investing activities				
Purchase of property, plant and equipment	-	-	(35,103)	-
Acquisition of businesses (note 3)	(1,360,000)	(1,200,000)	(5,995,599)	(1,200,000)
	(1,360,000)	-	(6,030,702)	(1,200,000)
Financing activities				
Proceeds from issuance of Units and Common Shares, net of issue costs (note 10)	1,171,927	799,873	5,813,511	1,308,920
Proceeds from exercise of Agent's Options (note 10)	-	-	27,075	-
Proceeds from exercise of Warrants	457	-	457	-
Interest payments	(54,916)	-	(114,416)	-
Proceeds from demand loan, net of transaction costs (note 9)	720,049	559,877	3,472,414	559,877
Repayment of demand loans	(144,922)	-	(290,464)	-
Repayment of convertible debenture	-	-	-	(185,756)
	1,692,595	1,359,750	8,908,577	1,683,041
Change in cash and cash equivalents for the period	275,640	73,603	1,683,820	83,351
Cash and cash equivalents – beginning of period	1,545,000	158,023	136,820	148,275
Cash and cash equivalents – end of period	1,820,640	231,626	1,820,640	231,626
Non-cash items:				
Broker shares/warrants issued as share issue costs	19,101	-	161,440	-
Exercise of Agents Options/Warrants	310	-	13,661	-
Assumption promissory note for acquisition of business	209,423	-	919,616	-

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.

Nova Leap Health Corp.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - United States dollars)

For the three and nine months ended September 30, 2018 and September 30, 2017

1. Nature of operations and going concern

Nature of operations

Nova Leap Health Corp. (the "Corporation") is the parent company and was incorporated under the Canada Business Corporations Act on November 16, 2015. The Corporation completed its Qualifying Transaction ("QT") on October 13, 2016. The principal activities of the Corporation and its subsidiaries (the "Group") is to provide skilled and non-medical home care to clients. The Group is currently operating home care services companies in the United States in Vermont, New Hampshire, Rhode Island and Massachusetts as well as in Nova Scotia, Canada. The Corporation's shares are listed on the TSX Venture Exchange and are traded under the symbol NLH.V.

These condensed interim consolidated financial statements include the accounts of the Corporation and its Canadian and United States subsidiaries. The registered head office of the Corporation is located at 2108-1969 Upper Water Street, Halifax, NS Canada B3J 3R7.

The condensed interim consolidated financial statements were approved by the Board of Directors on November 22, 2018.

Going concern

The Corporation completed its QT on October 13, 2016 and has subsequently acquired the home care assets of six additional businesses in the Northeastern United States and Eastern Canada to September 30, 2018. The Group achieved positive operating income excluding non-cash amortization and stock-based compensation in the second and third quarter of 2018. The positive operating income from the existing and acquired home care operations contribute to the Group's ability to increase overall operating income and improve cash flows from operations. On September 28, 2018, the Corporation acquired an additional business in Massachusetts and subsequent to September 30, 2018, the Corporation purchased an additional business in New Hampshire both of which historically have had positive cash flows from operations that are expected to further improve the Group's profitability and cash flows. (see note 3 – Business acquisitions and note 17 – Subsequent Events).

The Group's consolidated financial statements as at September 30, 2018 have been prepared based on International Financial Reporting Standards applicable to a going concern, which assumes the Group will continue in operation for the foreseeable future realizing its assets and settling its liabilities and commitments in the normal course of business. While the Group has begun to realize improved cash flows and results from operations, there is doubt about the appropriateness of the going concern assumption as the Group has not yet generated a history of positive cash flows or income from operations and currently has a working capital deficiency. The continuing operations of the Group are dependent on its ability to develop sustainable cash flow positive operations in the future and to raise adequate financing, if necessary. In the past, the Group has raised funds through equity and convertible debt offerings as well as demand loans to fund the purchase of home care assets.

There can be no assurance that the Group will be successful in achieving sustainable positive cash flows from operations or raising additional cash to finance operations. These condensed interim consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Group be unable to continue as a going concern, and these adjustments could be material.

2. Significant accounting policies

a) Statement of compliance

These unaudited condensed interim consolidated financial statements are prepared in accordance with IAS 34, Interim Financial Reporting ("IAS 34") as issued by the International Accounting Standards Board ("IASB"). These unaudited condensed interim consolidated financial statements were prepared using the same accounting policies and methods of computation and are subject to the same use of estimates and judgments, as the Corporation's consolidated financial statements for the year ended December 31, 2017. These unaudited condensed interim consolidated financial statements do not include all disclosures required by International Financial Reporting Standards ("IFRS") for annual consolidated financial statements and accordingly should be read in conjunction with the Corporation's audited consolidated financial statements for the year ended December 31, 2017, prepared in accordance with IFRS as issued by the IASB.

Nova Leap Health Corp.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - United States dollars)

For the three and nine months ended September 30, 2018 and September 30, 2017

2. Significant accounting policies (continued)

b) Revenue

The Group generates home and home health care revenues by providing home and home health care services directly to clients, such as dementia care, companionship, personal care, and skilled nursing care. The Group receives payments for providing services from private individuals, Government Agencies such as the Department of Veteran Affairs and long-term care insurance. Revenue is recognized at an hourly rate specified in client agreements and recognized as revenue at the time services are rendered. Revenue is only recognized to the extent that it is highly probable that a significant reversal will not occur.

The Corporation has determined that no significant financing components exist with respect to contracts with customers, as accounts receivable bear normal commercial credit terms and are non-interest bearing.

c) Accounting Changes

The Corporation has adopted the following new and revised standards, along with any consequential amendments, effective January 1, 2018. These changes were made in accordance with the applicable transition provisions.

IFRS 15, Revenue from Contracts with Customers

IFRS 15 presents new requirements for the recognition of revenue, replacing IAS 18 'Revenue', IAS 11 'Construction Contracts', and several revenue-related Interpretations. The new standard establishes a control-based revenue recognition model and provides additional guidance in many areas not covered in detail under existing IFRSs, including how to account for arrangements with multiple performance obligations, variable pricing, customer refund rights, supplier repurchase options, and other common complexities. The Corporation adopted IFRS 15 in its financial statements for the annual period beginning on January 1, 2018. The Corporation has elected to apply the modified retrospective method on transition, which means that comparative periods have not been restated. On transition, cumulative impacts related to adoption are required to be recognized in opening retained earnings. However, no adjustments were required by the Corporation.

IFRS 9, Financial Instruments

In July 2014, the IASB published IFRS 9 which replaces IAS 39 Financial Instruments: Recognition and Measurement ("IAS 39"). The replacement of IAS 39 is a three-phase project with the objective of improving and simplifying the reporting for financial instruments. The issuance of IFRS 9 provides guidance on the classification and measurement of financial assets and financial liabilities, and a new hedge accounting model with corresponding disclosures about risk management activity. The Company adopted IFRS 9 in its financial statements for the annual period beginning on January 1, 2018. The adoption of this standard has no financial impact to the Corporation.

- The Corporation did not identify any changes to the classification and measurement of the existing financial instruments upon applying IFRS 9, other than a change in the classification of cash and cash equivalents and accounts receivable from loans and receivables to assets at amortized cost, which had no impact on these financial statements.
- IFRS 9 requires the Corporation to record expected credit losses ("ECL") on the entire accounts receivable balance. The Corporation has applied the simplified approach and has calculated the lifetime ECLs based on an established provision matrix that considers the Corporation's historical loss experience, adjusted for forward-looking factors specific to the Corporation's clients and the economic environment. The adoption of the ECL requirements of IFRS 9 did not have an impact on the consolidated financial statements

d) Future accounting standards issued but not yet applied

IFRS 16, Leases

IFRS 16 was issued by the IASB in January 2016 and supersedes IAS 17, Leases. The new standard brings most leases on the balance sheet for lessees under a single model and eliminates the distinction between operating and finance leases. Lessor accounting remains largely unchanged. IFRS 16 becomes effective for annual periods beginning on or after January 1, 2019. The Corporation is currently evaluating the impact of IFRS 16 on its consolidated financial statements.

Nova Leap Health Corp.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - United States dollars)

For the three and nine months ended September 30, 2018 and September 30, 2017

3. Business acquisitions

Acquisition completed in the three months ended March 31, 2018

Family Tree Home Care, Inc. (“Family Tree”)

On February 23, 2018, the Corporation acquired the home care assets (“Significant Assets”) of Family Tree located in Shrewsbury, Massachusetts, USA. Pursuant to the terms of the Definitive Agreement, the Corporation’s U.S. subsidiary, Nova Leap Health MA, Inc., acquired the Significant Assets from Family Tree for a total purchase price of \$2,100,000. The acquisition was funded using \$450,000 cash, \$1,350,000 funds from debt and \$300,000 promissory note issued to Family Tree.

The details of the business acquisition are as follows:

Fair value of consideration transferred	
Cash	\$470,620
Promissory note to vendor	274,500
Demand loan, net of loan and legal fees	1,329,830
Total	\$2,074,950
Recognized amounts of identifiable net assets	
Prepaid security deposit	\$450
Intangible assets (customer lists)	640,000
Goodwill	1,434,500
Total	\$2,074,950

Goodwill

Goodwill of \$1,434,500 is primarily related to growth expectations, expected future profitability and the assembled workforce.

Acquisition costs

Total acquisition costs of \$93,302 were incurred and are included in professional fees on the Condensed Interim Consolidated Statement of Loss and Comprehensive Loss.

Contribution to Group results

Operating income of \$122,175 was earned for the period from the date of acquisition, February 23, 2018, to September 30, 2018 including \$93,302 of one-time acquisition costs. Revenue for the period from the date of acquisition, February 23, 2018, to September 30, 2018 was \$2,446,438.

Acquisitions completed in the three months ended June 30, 2018

Home Health Solutions Inc. (“Home Health”)

On April 14, 2018, the Corporation acquired the home care assets (“Significant Assets”) of Home Health located in Holyoke, Massachusetts, USA. Pursuant to the terms of the Definitive Agreement, the Corporation’s U.S. subsidiary, Nova Leap Health MA II, Inc., acquired the Significant Assets from Home Health for a total purchase price of \$1,200,000. The acquisition was funded using \$250,000 cash, \$750,000 funds from debt and \$200,000 promissory note issued to the vendors.

The details of the business acquisition are as follows:

Fair value of consideration transferred	
Cash	\$273,397
Promissory note to vendor	183,000
Demand loan, net of loan and legal fees	730,395
Total	\$1,186,792
Recognized amounts of identifiable net assets	
Prepaid expenses	\$3,792
Vehicle	9,000
Intangible assets (customer lists)	260,000
Goodwill	914,000
Total	\$1,186,792

Nova Leap Health Corp.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - United States dollars)

For the three and nine months ended September 30, 2018 and September 30, 2017

3. Business acquisitions (continued)

Home Health (continued)

Goodwill

Goodwill of \$914,000 is primarily related to growth expectations, expected future profitability and the assembled workforce.

Acquisition costs

Total acquisition costs of \$74,183 were incurred and are included in professional fees on the Condensed Interim Consolidated Statement of Loss and Comprehensive Loss.

Contribution to Group results

Operating income of \$20,843 was earned for the period from the date of acquisition, April 14, 2018, to September 30, 2018 including \$70,937 of one-time acquisition costs. Revenue for the period from the date of acquisition, April 14, 2018, to the reporting date was \$901,093.

Always Home Homecare Services Inc. (“Always Home”)

On June 1, 2018, the Corporation acquired Always Home Homecare Services Inc. located in Halifax, Nova Scotia, Canada. Pursuant to the terms of the Definitive Agreement, the Corporation’s Canadian subsidiary, 3315960 Nova Scotia Ltd., acquired the shares of Always Home for a total purchase price of \$2,121,259 (\$2,750,000 CAD). The acquisition was funded using \$1,079,914 (\$1,400,000 CAD) cash, \$771,367 (\$1,000,000 CAD) funds from debt and \$252,693 (\$350,000 CAD) promissory note issued to the vendors.

The details of the business acquisition are as follows:

Fair value of consideration transferred	
Cash	\$1,079,914
Promissory note to vendor	252,693
Demand loan, net of loan and legal fees	771,367
Working capital adjustment	159,702
	<hr/>
	\$2,263,676
Recognized amounts of identifiable net assets	
Working capital	\$159,702
Property, plant and equipment	6,682
Intangible assets (customer lists)	246,837
Brand	107,991
Goodwill	1,832,151
Deferred tax asset	20,310
Deferred tax liability	(109,997)
	<hr/>
	\$2,263,676

Goodwill

Goodwill of \$1,832,151 is primarily related to growth expectations, expected future profitability and the assembled workforce.

Acquisition costs

Total acquisition costs of \$50,354 were incurred and are included in professional fees on the Condensed Interim Consolidated Statement of Loss and Comprehensive Loss.

Contribution to Group results

Operating income of \$56,204 was earned for the period from the date of acquisition to the reporting date including \$8,187 of one-time acquisition costs. Revenue for the period from the date of acquisition, June 1, 2018, to the reporting date was \$761,040.

Acquisitions completed in the three months ended September 30, 2018

Comprehensive Home Care (“CHC”)

On September 28, 2018, the Corporation acquired the home care assets (“Significant Assets”) of CHC located in South Deerfield, Massachusetts, USA. Pursuant to the terms of the Definitive Agreement, the Corporation’s U.S. subsidiary, Nova Leap Health MA III, Inc., acquired the Significant Assets from CHC for a total purchase price of \$1,600,000. The acquisition was funded using \$615,486 cash, \$744,514 funds from debt and \$240,000 promissory note issued to the vendors.

Nova Leap Health Corp.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - United States dollars)

For the three and nine months ended September 30, 2018 and September 30, 2017

3. Business acquisitions (continued)

The details of the business acquisition are as follows:

Fair value of consideration transferred	
Cash	\$615,486
Promissory note to vendor	209,423
Demand loan, net of loan and legal fees	744,514
Total	\$1,569,423
Recognized amounts of identifiable net assets	
Intangible assets (customer lists)	310,000
Goodwill	1,259,423
	\$1,569,423

Goodwill

Goodwill is primarily related to growth expectations, expected future profitability and the assembled workforce.

Acquisition costs

Total acquisition costs of \$57,361 were incurred and are included in professional fees on the Condensed Interim Consolidated Statement of Loss and Comprehensive Loss.

Contribution to Group results

A loss from operating activities of \$58,255 was incurred for the period from the date of acquisition, September 28, 2018, to September 30, 2018 including \$51,847 of one-time acquisition costs. Revenue for the period from the date of acquisition, September 28, 2018, to the reporting date was \$17,829.

The identification and measurement of the fair values of the acquired assets from the Comprehensive Home Care acquisition is still subject to finalization.

Proforma Group Results and Other

Proforma Group results based on acquiring the assets of all closed acquisitions at January 1, 2018

If the Significant Assets of Family Tree, Home Health, CHC and the Always Home business were acquired during the period had been acquired on January 1, 2018, revenue of the Group for the reporting period would have increased by approximately \$4,515,000 and loss from operating activities for the period would have decreased by approximately \$679,000, excluding acquisition costs incurred.

Acquisition related expense

The Group incurred acquisition related expenses of \$83,673 for the three months ended September 30, 2018 (\$307,075 for the nine months ended September 30, 2018) of which \$47,286 related to the acquisition of businesses that closed in the three months ended September 30, 2018 (\$275,199 for the nine months ended September 30, 2018) and the remaining amount related to future or abandoned acquisitions.

4. Property plant & equipment

The changes in property, plant & equipment for the period are as follows:

	September 30, 2018	December 31, 2017
	\$	\$
Balance, beginning of period	3,225	-
Additions	35,103	3,500
Disposal	(1,325)	-
Amortization	(4,241)	(275)
Foreign exchange loss	1	-
Balance, end of period	32,763	3,225

Nova Leap Health Corp.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - United States dollars)

For the three and nine months ended September 30, 2018 and September 30, 2017

5. Intangible assets

The changes in intangible assets for the period are as follows:

	September 30, 2018	December 31, 2017
	\$	\$
Balance, beginning of period	226,493	5,700
Additions	1,564,829	260,000
Amortization	(388,362)	(35,316)
Impairment loss	-	(3,891)
Foreign exchange loss	101	-
Balance, end of period	1,403,061	226,493

The additions relate to the value of the customer lists acquired related to the purchase of the Significant Assets of Family Tree, Home Health and Comprehensive Home Care and the shares of Always Home during the period as well as the value for the brand related to the purchase of the Significant Assets of Comprehensive Home Care and the shares of Always Home during the period. (See note 3 above).

6. Goodwill

The changes in goodwill for the period are as follows:

	September 30, 2018	December 31, 2017
	\$	\$
Balance, beginning of period	2,116,500	180,000
Additions	5,440,073	1,936,500
Foreign exchange loss	2,689	-
Balance, end of period	7,559,262	2,116,500

The measurement of the fair values of the acquired assets and assumed liabilities from the Comprehensive Home Care acquisition is pending finalization (see note 3 above).

7. Related party transactions

Transactions with related parties were in the normal course of operations and are measured at the exchange amount, which is the amount agreed to by the parties.

During the three and nine months ended September 30, 2018, a company controlled by the CEO billed a total \$2,627 and \$10,687, respectively (\$4,729 and \$13,606 – September 30, 2017) for the rental of office space. As of August 1, 2018, the office space was no longer leased from a company controlled by the CEO as the head office changed locations.

Key management personnel

Key management personnel of the Group are members of the Board of Directors, as well as the Chief Executive Officer, the Chief Financial Officer and the Corporate Secretary. Key management personnel remuneration for the periods include the following expenses:

	Three months ended		Nine months ended	
	September 30, 2018	September 30, 2017	September 30, 2018	September 30, 2017
	\$	\$	\$	\$
Consulting fees	80,341	49,718	244,678	145,606
Directors fees	14,729	-	44,858	-
Stock based compensation	22,713	-	117,923	-
	117,783	49,718	407,459	145,606

As at September 30, 2018, there was \$78,133 included in Accounts payable and accrued liabilities for amounts owed to officers and directors of the Corporation (December 31, 2017 – \$167,073) for consulting fees, directors fees and expense reimbursements.

Nova Leap Health Corp.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - United States dollars)

For the three and nine months ended September 30, 2018 and September 30, 2017

8. Promissory Note

The changes in the promissory note for the period are as follows:

	September 30, 2018	December 31, 2017
	\$	\$
Balance, beginning of period	-	-
Issued	919,616	-
Effective interest	31,583	-
Foreign exchange loss	431	-
Balance, end of period	951,630	-
Current portion	455,553	-
Non-current portion	496,077	-

To finance a portion of acquisition of the assets of Family Tree, a subsidiary of the Corporation obtained a promissory note from the vendors with a principal amount of \$300,000. The loan bears interest at a rate of 3% per annum and \$150,000 plus accrued interest is repayable on January 31, 2019 and the remaining \$150,000 plus accrued interest is repayable on January 31, 2020. The promissory note was initially recorded at fair value using a market interest rate of 9% and subsequently measured at amortized cost using the effective interest rate method.

To finance a portion of acquisition of the assets of Home Health Solutions, a subsidiary of the Corporation obtained a promissory note from the vendors with a principal amount of \$200,000. The loan bears interest at a rate of 3% per annum and \$100,000 plus accrued interest is repayable on April 1, 2019 and the remaining \$100,000 plus accrued interest is repayable on April 1, 2020. The promissory note was initially recorded at fair value using a market interest rate of 9% and subsequently measured at amortized cost using the effective interest rate method.

To finance a portion of acquisition of the shares of Always Home Homecare, a subsidiary of the Corporation obtained a promissory note from the vendors with a principal amount of \$269,978 (\$350,000 CAD). The loan bears interest at a rate of 3% per annum and \$175,000 CAD plus accrued interest is repayable on May 31, 2019 and the remaining \$175,000 CAD plus accrued interest is repayable on May 31, 2020. The promissory note was initially recorded at fair value using a market interest rate of 7.45% and subsequently measured at amortized cost using the effective interest rate method.

To finance a portion of acquisition of the assets of Comprehensive Home Care, a subsidiary of the Corporation obtained a promissory note from the vendors with a principal amount of \$240,000. The loan bears interest at a rate of 2% per annum and \$80,000 plus accrued interest is repayable on October 1, 2019, October 1, 2020 and October 1, 2021. The promissory note was initially recorded at fair value using a market interest rate of 9% and subsequently measured at amortized cost using the effective interest rate method.

The promissory notes are subject to a Guaranty Agreement of Nova Leap Health Corp. and are subordinated to the demand loans in note 9.

9. Demand loans

The changes in the demand loans for the period are as follows:

	September 30, 2018	December 31, 2017
	\$	\$
Balance, beginning of period	540,545	-
Issued	3,631,916	600,000
Debt issue costs	(159,502)	(46,983)
Effective interest	169,049	15,285
Interest payment	(114,415)	(10,638)
Principal repayment in cash	(290,464)	(17,119)
Foreign exchange gain	12,408	-
Balance, end of period	3,789,537	540,545

Nova Leap Health Corp.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - United States dollars)

For the three and nine months ended September 30, 2018 and September 30, 2017

9. Demand loans (continued)

To finance the acquisition of the assets of Family Tree, the Corporation obtained a demand non-revolving loan with a principal amount of \$1,350,000. The loan bears interest at a rate of US Base Rate of 5.75% plus 1.5%. The loan is repayable on demand and \$20,378 blended payments of both principal and interest are paid monthly. The amortization period of the loan is 84 months from the date of drawdown, February 23, 2018. Export Development Canada provided a 75% guarantee for the loan for a fee of 2.35% per annum. The loan is designated as an “other financial liability” and was initially recorded at \$1,308,497 which was fair value of \$1,350,000 adjusted for transaction expenses of \$41,503, of which, \$21,332 were paid directly by the Corporation.

To finance the acquisition of the assets of Home Health Solutions, the Corporation obtained a demand non-revolving loan with a principal amount of \$750,000. The loan bears interest at a rate of US Base Rate of 5.75% plus 1.5%. The loan is repayable on demand and \$14,763 blended payments of both principal and interest are paid monthly. The amortization period of the loan is 60 months from the date of drawdown, April 12, 2018. Export Development Canada provided a 75% guarantee for the loan for a fee of 2.35% per annum. The loan is designated as an “other financial liability” and was initially recorded at \$714,617 which was fair value of \$750,000 adjusted for transaction expenses of \$35,383 of which, \$15,778 were paid directly by the Corporation.

To finance the acquisition of the assets of Always Home Homecare, the Corporation obtained a demand non-revolving loan with a principal amount of \$771,367 (\$1,000,000 CAD). The loan bears interest at a rate of CAD Prime Rate of 3.7% plus 2%. The loan is repayable on demand and \$14,488 (\$19,078 CAD) blended payments of both principal and interest are paid monthly. The amortization period of the loan is 60 months from the date of drawdown, June 4, 2018. The loan is designated as an “other financial liability” and was initially recorded at \$746,753 which was fair value of \$771,367 adjusted for transaction expenses of \$24,614, of which, \$16,565 were paid directly by the Corporation.

To finance the acquisition of the assets of Comprehensive Home Care Corporation obtained a demand non-revolving loan with a principal amount of \$772,499 (CAD\$1,000,000). The loan bears interest at a rate of CAD Prime Rate of 3.7% plus 1.5%. The loan is repayable on demand and \$15,006 (\$19,426 CAD) blended payments of both principal and interest are paid monthly. The amortization period of the loan is 60 months from the date of drawdown, September 28, 2018. Export Development Canada provided a 50% guarantee for the loan for a fee of 2.35% per annum. The loan is designated as an “other financial liability” and was initially recorded at \$732,004 which was fair value of \$767,451 adjusted for transaction expenses of \$35,447 of which, \$12,510 were paid directly by the Corporation.

All the loans are also secured through a registered General Security Agreement and a Corporate Guarantee for the principal amount of the loan from Nova Leap’s US and Canadian subsidiaries.

10. Common shares

a. Authorized:

Unlimited number of common shares, without nominal or par value

b. Issued and outstanding:

	September 30, 2018		December 31, 2017	
	Number of Shares	Value \$	Number of Shares	Value \$
Balance, beginning of period	29,722,100	2,596,157	13,500,000	510,801
Shares issued for acquisition of assets	-	-	2,509,600	400,000
Shares issued for cash, net of issue costs	27,964,611	5,275,669	13,712,500	1,685,356
Broker shares issued	80,000	15,787	-	-
Agent options exercised	350,000	40,736	-	-
Warrants exercised	2,400	767	-	-
Balance, end of period	58,119,111	7,929,116	29,722,100	2,596,157

On January 8, 2018, the Corporation closed a non-brokered private placement and raised gross proceeds of \$382,386 (\$475,000 CAD) net of share issue costs of \$19,140 through the issuance of 2,375,000 Units at a price of \$0.20 CAD per unit. Each unit is comprised of one common share of the Corporation and a one-half common share purchase warrant. Two half warrants entitle the holder to acquire one common share of the Corporation for \$0.35 CAD for a period of 24 months from the closing date. \$82,209 (CAD \$102,121) was allocated to the warrants based on the fair value of the warrants, net of

Nova Leap Health Corp.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - United States dollars)

For the three and nine months ended September 30, 2018 and September 30, 2017

10. Common shares (continued)

proportional amount of the related share issue costs. The Corporation applies the fair value method with respect to the measurement of shares and warrants issued as private placement units. The Company allocates the net proceeds based on the relative fair values to each component. The fair value of the warrants was determined using the Black-Scholes pricing model. All securities issued pursuant to the private placement are subject to a 4 month hold period that expired on May 7, 2018.

On February 22, 2018, the Corporation closed a brokered private placement and raised gross proceeds of \$1,350,845 (\$1,711,250 CAD) net of share issue costs of \$208,152 through the issuance of 6,845,000 Units at a price of \$0.25 CAD per unit. Each unit is comprised of one common share of the Corporation and a one-half common share purchase warrant. Two half warrants entitle the holder to acquire one common share of the Corporation for \$0.375 CAD for a period of 24 months from the closing date. \$280,730 (CAD \$355,628) was allocated to the warrants based on the fair value of the warrants, net of proportional amount of the related share issue costs. The Corporation paid the Agents a corporate finance fee of which \$15,787 (\$20,000 CAD) was paid through the issuance of 80,000 Common Shares at a deemed price of \$0.25 per Common Share.

On April 13, 2018, the Corporation closed the first tranche of a brokered private placement and raised gross proceeds of \$798,642 (\$1,006,050 CAD) net of share issue costs of \$114,092 through the issuance of 3,353,499 common shares at a price of \$0.30 CAD per share. All common shares issued pursuant to the private placement are subject to a 4 month hold period that expires on August 12, 2018. The Corporation paid the Agents a cash commission of \$53,937 and issued 221,879 agents' warrants.

On May 31, 2018, the Corporation closed the second tranche of a brokered private placement and raised gross proceeds of \$1,843,837 (\$2,387,400 CAD) through the issuance of 7,957,999 common shares at a price of \$0.30 CAD per share and also closed a non-brokered private placement and raised gross proceeds of \$671,269 (\$869,160 CAD) through the issuance of 2,897,198 common shares at a price of \$0.30 CAD per share net of total share issue costs of \$219,814. All common shares issued pursuant to the private placement are subject to a 4 month hold period that expires on September 30, 2018. The Corporation paid the Agents a cash commission of \$147,247 and issued 418,060 agents' warrants.

On September 28, 2018, the Corporation closed the first tranche of a brokered private placement and a non-brokered private placement for combined gross proceeds of \$1,226,396 (\$1,587,570 CAD) net of share issue costs of \$73,571 through the issuance of 4,535,915 common shares at a price of \$0.35 CAD per share. All common shares issued pursuant to the private placement are subject to a 4 month hold period that expires on January 28, 2019. The Corporation paid the Agents a cash commission of \$28,956 and issued 107,097 agents' warrants.

Common shares subject to escrow

Of the 10,000,000 common shares issued in January 2016 which were subject to an escrow agreement, 4,500,000 shares were in escrow at September 30, 2018. The remaining shares in escrow will be released in 3 equal increments of 1,500,000 shares each, every 6 months with the final release on November 4, 2019.

11. Warrants

The changes in warrants for the period are as follows:

	September 30, 2018	December 31, 2017
	\$	\$
Balance, beginning of period	399,980	-
Warrants issued, net of issue costs	345,579	399,980
Broker warrants issued	176,477	-
Broker warrants exercised	(310)	-
Balance, end of period	921,726	399,980

Nova Leap Health Corp.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - United States dollars)

For the three and nine months ended September 30, 2018 and September 30, 2017

11. Warrants (continued)

	September 30, 2018			December 31, 2017		
	Number	Weighted Average Exercise Price (CAD)	Remaining contractual life (years)	Number	Weighted Average Exercise Price CAD	Remaining contractual life (years)
Balance, beginning	6,856,250	\$0.35	0.77	-	-	-
Issued for cash	4,610,000	\$0.37	1.36	-	-	-
Broker warrants issued	1,108,136	\$0.29	1.39	6,856,250	\$0.35	1.52
Broker warrants exercised	(2,400)	\$0.25	-	-	-	-
Balance, end	12,571,986	\$0.35	1.04	6,856,250	\$0.35	1.52

On January 8, 2018, in connection with the private placement, the Corporations issued 1,187,500 warrants with an exercise price of \$0.35 CAD and expire on January 7, 2020. The fair value of the warrants issued, net of share issue costs allocation was \$82,209 (CAD \$102,121). The Corporation also issued 36,300 broker warrants with an exercise price of \$0.35 CAD and expire on February 21, 2020.

On February 22, 2018, in connection with the brokered private placement, the Corporations issued 3,422,500 warrants with an exercise price of \$0.375 CAD and expire on February 21, 2020. The fair value of the warrants issued, net of share issue costs allocation was \$280,730 (CAD \$355,628). The Corporation also issued 324,800 broker warrants with an exercise price of \$0.25 CAD and expire on February 21, 2020.

On April 13, 2018, in connection with the first tranche of a brokered private placement, the Corporations issued 221,879 broker warrants with an exercise price of \$0.30 CAD and expire on April 12, 2020. The fair value of the broker warrants issued was \$45,795 (CAD \$57,689).

On May 31, 2018, in connection with the second and final tranche of a brokered private placement, the Corporations issued 418,060 broker warrants with an exercise price of \$0.30 CAD and expire on May 30, 2020. The fair value of the broker warrants issued was \$64,575 (CAD \$83,612).

On September 28, 2018, in connection with the first tranche of a brokered private placement, the Corporations issued 107,097 broker warrants with an exercise price of \$0.35 CAD and expire on September 27, 2020. The fair value of the broker warrants issued was \$19,101 (CAD \$24,726).

The following weighted average assumptions were used in the Black-Scholes option pricing model for the period:

	Three months ended		
	March 31, 2018	June 30, 2018	September 30, 2018
Exercise price (CAD)	\$0.36	\$0.30	\$0.35
Risk free interest rate	1.25%	1.75%	2.20%
Expected volatility	142%	139%	129%
Expected dividend yield	0%	0%	0%
Expected life	2.0 years	2.0 years	2.0 years
Grant date fair value (CAD)	\$0.24	\$0.22	\$0.23

Nova Leap Health Corp.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - United States dollars)

For the three and nine months ended September 30, 2018 and September 30, 2017

11. Warrants (continued)

The following table summarizes information concerning outstanding and exercisable warrants at September 30, 2018:

Expiry date	Number	Exercise price (CAD) \$
Mar 9, 2019	1,750,000	0.35
Jul 5, 2019	2,631,250	0.35
Oct 5, 2019	2,475,000	0.35
Jan 7, 2020	1,223,800	0.35
Feb 22, 2020	3,422,500	0.375
Feb 22, 2020	322,400	0.25
Apr 12, 2020	221,879	0.30
May 30, 2020	418,060	0.30
September 27, 2020	107,097	0.35
	12,571,986	0.35

12. Stock based compensation

The Corporation has a common share purchase option plan (the "Plan") for directors, officers, employees and consultants. The total number of options issued and outstanding at any time cannot exceed 10% of the issued and outstanding common shares of the Corporation unless shareholder and regulatory approvals are obtained. Options granted under the Plan have a ten-year term and are non-transferable. Options vesting conditions are determined by the Board of Directors at the time of grant. Options may be exercised ninety days following the date of termination of employment or holding office as a director or officer of the Corporation and, in the case of death, expire within one year thereafter. Options are granted at a price no lower than the market price of the common shares less any discounts allowed by the TSX Venture Exchange at the time of the grant.

The changes in incentive stock options during the period were as follows:

	September 30, 2018		December 31, 2017	
	Number	Weighted Average Exercise Price (CAD)	Number	Weighted Average Exercise Price (CAD)
Balance, beginning	1,350,000	\$0.10	1,350,000	\$0.10
Granted	1,485,000	\$0.25	-	-
Balance, end	2,835,000	\$0.18	1,350,000	\$0.10

On January 12, 2018, the Corporation granted 1,485,000 incentive stock options to directors, officers, employees and consultants of the Corporation. The stock options are exercisable for a period of 10 years at an exercise price of \$0.25 CAD per share and vest 25% immediately and 25% on each anniversary date of the stock option grant date.

The following table summarizes information concerning outstanding and exercisable options at September 30, 2018:

Expiry date	Outstanding		Exercisable	
	Number	Exercise price (CAD) \$	Number	Exercise price (CAD) \$
Apr 25, 2026	1,350,000	\$0.10	1,350,000	\$0.10
Jan 11, 2028	1,485,000	\$0.25	371,250	\$0.25
	2,835,000	\$0.18	1,721,250	\$0.13

The weighted average contractual life outstanding as at September 30, 2018 is 8.47 years.

Nova Leap Health Corp.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - United States dollars)

For the three and nine months ended September 30, 2018 and September 30, 2017

12. Stock based compensation (continued)

The compensation cost for the stock options granted during the period were determined based on the fair value of the options at the date of grant using the Black-Scholes option pricing model with the following assumptions:

Option grant date	January 12, 2018
Exercise price (CAD)	\$0.25
Risk free interest rate	1.00%
Expected volatility	107%
Expected dividend yield	0%
Expected life	6.0 years
Grant date fair value (CAD)	\$0.20

The expected volatility was determined based on the historical share price volatility from the date of the grant over a period of time equal to the expected life of the option. The expected forfeiture rate was nil.

The Corporation recorded total stock-based compensation during the three and nine months ended September 30, 2018 of \$26,248 and \$134,395, respectively (2017 - nil).

The changes in Agent's stock options during the period were as follows:

Expiry date	Number of options	Exercise Price (CAD)
		\$
Balance, beginning	350,000	0.10
Exercised	(350,000)	(0.10)
Balance, end	-	-

13. Contributed Surplus

The changes in contributed surplus for the period are as follows:

	September 30, 2018	December 31, 2017
	\$	\$
Balance, beginning of period	107,975	116,109
Stock options granted – directors and officers	134,395	-
Exercise stock options - agents	(13,661)	-
Repayment of convertible debentures in cash	-	(8,134)
Balance, end of period	228,709	107,975

14. Loss per Share

Basic earnings (loss) per share is calculated based on the weighted average number of shares outstanding during the period. Diluted earnings per share assumes that convertible debentures, stock options, agent's options and warrants have been exercised on the later of the beginning of the period and the date granted. As of September 30, 2018, all options, warrants and convertible debentures were excluded from the computation of diluted loss per share because their effect would have been anti-dilutive.

15. Financial instruments

The Group is exposed to various risks in relation to financial instruments. The main types of risks are credit risk, liquidity risk and market risk. The Group is exposed to the same risk in the current year as it was exposed to in the prior year and in addition is exposed to interest rate risk because of the demand loan that has variable rate interest. The most significant financial risks to which the Group is exposed are described below.

Credit risk

Credit risk is the risk that a counterparty fails to discharge an obligation to the Group. The Group is exposed to this risk for various financial instruments, for example by granting receivables to customers and placing deposits. The Group's maximum exposure to credit risk is limited to the carrying amount of financial assets recognized at the end of the reporting period, as summarized below:

Nova Leap Health Corp.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - United States dollars)

For the three and nine months ended September 30, 2018 and September 30, 2017

15. Financial instruments (continued)

Classes of financial assets – carrying amounts	September 30, 2018	December 31, 2017
	\$	\$
Cash and cash equivalents	1,820,640	136,820
Accounts receivable	1,207,762	269,947
	3,028,402	406,767

In respect of trade account receivables, the Group is exposed to a certain level of credit risk as the amounts are uncollateralized. Credit risk for accounts receivable is the risk of loss associated with a client's inability to fulfil its payment obligations. The largest exposure to credit risk is in relation to receivables. The Group mitigates credit risk by both collecting client deposits prior to service for certain clients and actively monitoring the aging of accounts receivable and regularly follows up on overdue accounts. As at September 30, 2018, the Group had \$64,776 collected for client deposits, representing approximately 5% of outstanding accounts receivable, billed and accrued (December 31, 2017 - \$99,463). Management believes that counterparty concentrations are in the normal course of business and are not unusual.

The credit risk for cash and cash equivalents is considered low as the Group maintains most of its cash with a Schedule I bank in Canada.

Liquidity risk

Liquidity risk is the risk that the Group might be unable to meet its current and future obligations. The Group's approach to managing liquidity risk is to closely monitor working capital balances as compared to budgeted upcoming expenses and expected due diligence and acquisition expenses. During the current and previous period, the Group raised funds, primarily through private placements or demand loans. As at September 30, 2018, the Group had a cash and cash equivalents balance of \$1,820,640. The Group has a working capital shortfall at September 30, 2018 primarily due to the presentation of demand loans as current, and the Group's ability to continue to meet its liabilities when due, beyond the current cash balance, is dependent on the growth of the home care business acquired as well as future support of shareholders through public or private equity offerings. Refer to note 1, Going Concern.

The following table shows the timing of cash outflows relating to its liabilities:

	< 1 year	1-2 years	3-5 years	> 5 years
	\$	\$	\$	\$
Account payable and accrued liabilities	726,885	-	-	-
Client deposits	64,776	-	-	-
Demand loan	973,797	956,806	2,528,351	349,908
Promissory note	465,187	465,187	80,000	-

Market risk

The Group is exposed to market risk through its use of financial instruments and specifically to currency risk, which result from both its operating and financing activities.

Foreign currency sensitivity

The Group's operations are carried out in USD. Exposure to currency exchange rates arise from the fact that the Group's equity offerings have been denominated in CAD and will be denominated in CAD for the foreseeable future as the Corporation's shares are listed on a Canadian stock exchange and the Group has one operation in Canada that transacts in Canadian dollars. The Group's exposure to CAD dollar currency risk was as follows:

	September 30, 2018	December 31, 2017
	(CAD)	(CAD)
	\$	\$
Cash and cash equivalents	1,592,538	72,346
Accounts receivable	413,659	-
Accounts payable & accrued liabilities	(449,626)	(274,793)
Demand loan	(1,867,647)	-
Promissory note	(335,803)	-
	(646,879)	(202,447)

Nova Leap Health Corp.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - United States dollars)

For the three and nine months ended September 30, 2018 and September 30, 2017

15. Financial instruments (continued)

Sensitivity to a plus or minus 5.0% change in the CAD dollar exchange rate would affect net loss and comprehensive loss and deficit by approximately \$25,000.

Interest rate sensitivity

As at September 30, 2018, the Group is exposed to changes in market interest rates through bank borrowings at variable interest rates. Sensitivity if interest rates increased or decreased by 1% would affect net loss and comprehensive loss and deficit by approximately \$119,000 over the remaining term of the loans.

Fair value

All financial assets and liabilities except for the demand loans and promissory notes are short-term. The carrying values of short-term financial assets and liabilities are a reasonable approximation of fair value. The fair value of the demand loans is approximately \$3,941,264 as at September 30, 2018. The fair value of the promissory notes is approximately \$1,010,375 as at September 30, 2018.

16. Segment reporting

As of September 30, 2018, management identified the Group's reportable segments as Canadian operations and US operations. All businesses provide home care services to clients, with Corporate providing management oversight and expertise, and growth through acquisitions of additional business. These operating segments are monitored by the Group's Chief Executive Officer and strategic decisions are made based on segment operating results.

As a result of ongoing acquisitions, management re-evaluated the Corporation's reportable segments for the period ended September 30, 2018 and has restated the prior period segmented disclosure as a result.

Segment information for the reporting period is as follows:

	For the three months ended September 30, 2018		
	US \$	Canada \$	Total \$
Segment revenues			
(all from external customers)	2,309,911	561,099	2,871,010
Cost of services	1,584,656	407,179	1,991,835
Gross Profit	725,255	153,920	879,175
General & administrative	632,951	116,601	749,552
Segment operating income (a)	92,304	37,319	129,623
Segment assets	8,487,295	2,570,013	11,057,308

- a) US Segment operating income includes non-cash expenses related to amortization of customer lists and stock-based compensation of \$149,682. Canada Segment operating income includes non-cash expenses related to amortization of customer lists of \$29,575.

	For the three months ended September 30, 2017		
	US \$	Canada \$	Total \$
Segment revenues			
(all from external customers)	88,682	-	88,682
Cost of services	54,653	-	54,653
Gross Profit	34,029	-	34,029
General & administrative	47,948	-	47,948
Segment operating loss (a)	(13,919)	-	(13,919)
Segment assets	1,534,857	-	1,534,857

- a) US Segment operating income includes non-cash expenses related to amortization of customer lists and impairment loss of \$3,300.

Nova Leap Health Corp.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - United States dollars)

For the three and nine months ended September 30, 2018 and September 30, 2017

16. Segment reporting (continued)

	For the nine months ended September 30, 2018		
	US \$	Canada \$	Total \$
Segment revenues (all from external customers)	5,800,945	760,152	6,561,097
Cost of services	3,903,458	547,599	4,451,057
Gross Profit	1,897,487	212,553	2,110,040
General & administrative	1,740,354	159,008	1,899,362
Segment operating income (a)	157,133	53,545	210,678
Segment assets	8,487,295	2,570,013	11,057,308

- a) US Segment operating income includes non-cash expenses related to amortization of customer lists and stock-based compensation of \$363,086. Canada Segment operating income includes non-cash expenses related to amortization of customer lists of \$39,767.

	For the nine months ended September 30, 2017		
	US \$	Canada \$	Total \$
Segment revenues (all from external customers)	168,649	-	168,649
Cost of services	107,880	-	107,880
Gross Profit	60,769	-	60,769
General & administrative	118,958	-	118,958
Segment operating loss (a)	(58,189)	-	(58,189)
Segment assets	1,534,857	-	1,534,857

- a) US Segment operating income includes non-cash expenses related to amortization of customer lists and impairment loss of \$5,700.

The Group's revenues from external customers and its non-current assets are all attributable to the US and Canada segments. Revenues from external customers are identified based on the client's geographical location. Non-current assets are allocated based on their physical location.

The totals presented in the Group's operating segments reconcile to the key financial figures as presented in the financial statements as follows:

	For the three months ended		For the nine months ended	
	September 30, 2018 \$	September 30, 2017 \$	September 30, 2018 \$	September 30, 2017 \$
Revenues (Segment and Group)	2,871,010	88,682	6,561,097	168,649
Gross profit (Segment and Group)	879,175	34,029	2,110,040	60,769
Group loss				
Total reportable segment operating Income (loss)	129,623	(13,919)	210,678	(58,189)
Corporate and administrative expenses not allocated	(291,986)	(160,943)	(817,377)	(430,617)
Group operating loss	(162,363)	(174,862)	(606,699)	(488,806)

Nova Leap Health Corp.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - United States dollars)

For the three and nine months ended September 30, 2018 and September 30, 2017

16. Segment reporting (continued)

	September 30, 2018	September 30, 2017
	\$	\$
Assets		
Total reportable segment assets	11,057,308	1,534,857
Group headquarters	1,272,625	198,966
Group assets	12,329,933	1,733,823

17. Subsequent events

On October 19, 2018, the Corporation completed the acquisition of the business assets of Living at Home SeniorCare located in Amherst, New Hampshire. The acquired business will begin to operate under one of Nova Leap's existing brands, Armistead Senior Care, which has operations in Vermont and New Hampshire. The acquisition was made for total consideration of \$425,000 of which \$325,000 was payable with cash on closing and \$100,000 is by way of a promissory note. The promissory note bears interest at 6%. Three equal principal payments are to be made on September 1, 2019, September 1, 2020 and September 1, 2021 along with the accrued interest.

On October 25, 2018, Nova Leap closed the second tranche of a brokered and non-brokered private placement and raised gross proceeds of \$407,081 (\$532,299 CAD) through the issuance of 1,520,855 shares at a price of \$0.35 CAD per share. All common shares issued pursuant to the private placement are subject to a 4 month hold period that expires on February 24, 2019. The Corporation paid the Agents a cash commission of \$12,606 and issued 47,097 agents' warrants as well as an additional fee comprised of approximately \$2,217 in cash and 8,300 in agents' warrants. Each agents' warrant is exercisable for one Common Share at a price of \$0.35 for a period of 24 months from the closing of the second tranche of the Brokered Offering.

18. Comparative figures

Certain comparative figures have been adjusted to conform to changes in the current year presentation.